Datroway significantly improves overall and progression-free survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy. TROPION-Breast02 trial results highlight ...

In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...

A real-world analysis of more than 60,000 patients in the US finds median survival increased by almost 7 months from 2011 to ...

Patients with HER2-positive advanced breast cancers had the greatest benefits, with survival improvements ranging from ...

Over the past decade, we have seen new approvals of therapies in advanced triple negative breast cancer that have not only prolonged progression-free survival, but also overall survival. So, for ...

So, I think more to come on how first line selection might evolve in the next few years depending on results from other ...

Positive results from the TROPION-Breast02 Phase III trial showed DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated a statistically significant and clinically meaningful improvement for the dual ...

People diagnosed with advanced breast cancer in 2025 can expect to live for an extra six or seven months, compared to the ...

Tecentriq with chemotherapy did not significantly improve EFS in TNBC patients, with a four-year EFS rate of 85.2% versus 81.9% for placebo. No overall survival benefit was observed with Tecentriq, ...

Our stories are reviewed by medical professionals to ensure you get the most accurate and useful information about your health and wellness. For more information, visit our medical review board. This ...

March 28, 2007 — A new study clearly reveals the survival disadvantage for the so-called "triple-negative" subtype of breast cancer compared with other types of breast cancer. These tumors test ...